



Thomas A. Blinka  
+1 202 842 7865  
tblinka@cooley.com

The Directors  
Amryt Pharma plc  
Department 920a  
196 High Road, Wood Green  
London N22 8HH  
United Kingdom

23 August 2019

Dear Sirs:

**Amryt Pharma plc (the “Company”) – Consent Letter**

We, Cooley LLP, refer to the admission document of the Company to be dated 27 August 2019 relating to, among other things, the acquisition of Aegerion Pharmaceuticals, Inc. (“**Aegerion**”), the scheme of arrangement and the applications for admission of the entire issued share capital of a new holding company of the Company to AIM and the Euronext Growth Market (the “**Admission Document**”).

We hereby give our consent to the inclusion in the Admission Document of our patent report relating to the Company dated 23 August 2019 and the references to our name generally in the form and context in which they are included, as shown in the enclosed proof of the Admission Document initialed by us for the purpose of identification.

Our consent is required by Annex 1 item 1.3 of Commission Delegated Regulation (EU) No 2019/980 as applied by paragraph (a) of Schedule Two to the AIM Rules for Companies and paragraph (a) of Schedule Two of Chapter 5 of the Euronext Growth Market Rules for Companies and is given for the purpose of complying with those provisions and for no other purpose.

Yours faithfully,

A handwritten signature in black ink that reads "Thomas A. Blinka".

Thomas A. Blinka  
Cooley LLP

209530799 v1